Navigation Links
Raptor Pharmaceuticals Closes $10 Million Private Placement
Date:6/30/2008

ressing orphan indications."

Kim R. Tsuchimoto, Raptor's Chief Financial Officer, stated, "This funding is critical for the execution of our drug development programs. We are grateful to our existing and new investors who support our passionate efforts in bringing safer and more effective therapeutics to market."

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") consists of a preclinical division and a clinical division, which together form a continuous set of specialized competencies to develop Raptor's pipeline of drug product candidates from early stage to clinical stage through to commercialization. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins, while Raptor's clinical division advances clinical-stage product candidates towards marketing approval and commercialization. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH").

Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target delivery to the liver to potentially treat primary liver cancer and hepatitis. NeuroTrans(TM) represents engineered RAP peptides created to target receptors in the brain and are currently undergoing preclinical evaluation at Stanford University for their ability to enhance the transport of therapeutics across the blood-brain barrier.

Raptor's clinical division executes the clinical development of: 1) Raptor's internally developed product candidates; 2) new chemical entities in-licensed for mid-to-late stage clinical development; 3) currently approved drugs with potential in additional indications; and 4) treatments that may be repurposed or reformulated fo
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 ... en 1974, a été depuis 40 ... les évaluations cliniques traditionnelles par des évaluations ... et sur les impacts économiques des traitements. ... A cours d,une récente ...
(Date:9/18/2014)...   Sigma-Aldrich Corporation (Nasdaq: ... a new gene editing partnership with the University ... the partnership, Sigma-Aldrich will provide the Vector Core ... dedicated gene editing bioinformaticians. The partnership ... the U-M Medical School. One initiative already underway, ...
(Date:9/18/2014)... 2014 OMICS Group International invites ... participate in the ‘Open Access Week’ by actively ... OMICS Group Pharma Journals from 20-26th October, ... fastest emerging Sciences, accelerating with a tremendous speed ... the globe. The industry is gearing with innovation ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... ... sectors suffer, savvy investors like Prudential target healthcare , ... Minneapolis (Vocus) – Even as other commercial real ... healthcare real estate. Recent deals have included $250 million in new debt and $30 ...
... , BETHESDA, Md., July 30 Micromet, Inc. ... proprietary antibodies for the treatment of cancer, inflammation and autoimmune ... 14,000,000 shares of its common stock at a public offering ... are being offered by Micromet. The gross proceeds to ...
... , , , ... CRTX ), a specialty pharmaceutical company focused ... the respiratory and related markets, today announced that it ... a leading European pharmaceutical company headquartered in Parma, Italy. ...
Cached Biology Technology:Millions Flowing into Medical Real Estate 2Millions Flowing into Medical Real Estate 3Micromet Announces Pricing of Public Offering of Common Stock 2Micromet Announces Pricing of Public Offering of Common Stock 3Micromet Announces Pricing of Public Offering of Common Stock 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 2Cornerstone Therapeutics Announces Closing of Chiesi Transaction 3Cornerstone Therapeutics Announces Closing of Chiesi Transaction 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 5Cornerstone Therapeutics Announces Closing of Chiesi Transaction 6
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... world, are the ideal animal in which to study ... the ocean into tens of thousands of freshwater streams ... skeleton to adapt to the new environment. , Breeding ... have turned up one of the genes that controls ... that gene,s regulation in a freshwater population is associated ...
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
Breaking Biology News(10 mins):How stress tears us apart 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Transparent larvae hide opaque eyes behind reflections 2
... , This release is available in Spanish . ... Agriculture (USDA) scientists working as part of an international team have ... in the journal Nature reported today. The achievement ... speed up development of wheat varieties with enhanced nutritional value. ...
... part of their ongoing research on the role of ... Diabetes Center scientists, in collaboration with scientists at the ... associated with type 1 diabetes and other autoimmune diseases ... upcoming issue of Diabetes . Recent studies ...
... aestivum ) is one of the "big three" globally important ... Fully 35% of the world,s 7 billion people depend on ... scientists, including a group from Cold Spring Harbor Laboratory (CSHL), ... The study reveals the evolution of bread wheat ...
Cached Biology News:USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 3Joslin researchers increase understanding of genetic risk factor for type 1 diabetes 2Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Fluorescence Test Plate consists of an ... with Inert Organic Fluorescent Compounds embedded in ... used on BioTeks FLx800 and Synergy Multi-Detection ... for GLP compliance while reducing the need ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 2-year license ... NFP/Academic accounts , * ...
Biology Products: